![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Myriad’s BRACAnalysis CDx Test Identifies Patients Who Would Benefit from Olaparib
Myriad’s BRACAnalysis CDx Test Identifies Patients Who Would Benefit from Olaparib
![](https://www.fdanews.com/ext/resources/test/Device_Images5/IVImage.gif?t=1477525763&width=430)
Myriad Genetics revealed its BRACAnalysis CDx test accurately identified patients who may benefit from treatment with olaparib.
The device was included in the SOLO2 study (NCT01874353) as a diagnostic with olaparib, an oral PARP inhibitor being developed by AstraZeneca.
In the clinical study, patients were tested for germline BRCA (gBRAC+) mutations as determined by Myriad’s BRACAnalysis CDx test, and the primary endpoint for SOLO2 was progression-free survival. — Cynthia Jessup
Upcoming Events
-
21Oct